Effect of N‑terminal region of human parvovirus B19‑VP1 unique region on cardiac injury in naïve mice

Hung,Kuo-Chuan; Huang,Zi-Yun; Yow,Jia Le; Hsu,Tsai-Ching; Tzang,Bor-Show

doi:10.3892/mmr.2021.12399

Effect of N‑terminal region of human parvovirus B19‑VP1 unique region on cardiac injury in naïve mice

Authors:
- Kuo-Chuan Hung
- Zi-Yun Huang
- Jia Le Yow
- Tsai-Ching Hsu
- Bor-Show Tzang
View Affiliations

Affiliations: Department of Anesthesiology, Chi Mei Medical Center, Tainan 710, Taiwan, Institute of Medicine, College of Medicine, Chung Shan Medical University, Taichung 402, Taiwan
Published online on: September 2, 2021 https://doi.org/10.3892/mmr.2021.12399
Article Number: 759
Copyright: © Hung et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A unique region of human parvovirus B19 virus‑VP1 (B19V‑VP1u) has been linked to a variety of cardiac disorders. However, the precise role of B19V‑VP1u in inducing cardiac injury remains unknown. The present study investigated the effects of B19V‑VP1u and different regions of B19V‑VP1u, including B19V‑VP1uA (residues 1‑60), B19V‑VP1uB (residues 61‑129), B19V‑VP1uC (residues 130‑195) and B19V‑VP1uD (residues 196‑227), on inducing cardiac injury in naïve mice by zymography, immunoblotting, H&E staining and cytokine immunoassay. A significantly higher MMP‑9/MMP‑2 ratio and increased levels of inflammatory cytokines, including IL‑6 and IL‑1β, were detected in the left ventricles of the mice injected with B19V‑non‑structural protein 1 (B19V‑NS1) and B19V‑VP1u, accompanied by increased expression levels of phosphorylated (p‑)ERK and p‑P38. Significantly upregulated expression levels of atrial natriuretic peptide (ANP), heart‑type fatty acid‑binding protein (H‑FABP) and creatine kinase isoenzyme‑MB (CK‑MB), which are well‑known cardiac injury markers, as well as increased infiltration of lymphocytes, were detected in the left ventricles of the mice injected with B19V‑VP1, B19V‑NS1 and B19V‑VP1u. Moreover, a significantly higher MMP‑9/MMP‑2 ratio and increased levels of IL‑6 and IL‑1β were observed in the left ventricles of the mice injected with B19V‑VP1u, B19V‑VP1u‑A, B19V‑VP1u‑B and B19V‑VP1u‑C, accompanied by upregulated p‑ERK and p‑P38 expression. Notably, significantly lower levels of IL‑6 and IL‑1β were observed in the left ventricles of the mice injected with B19V‑VP1uD. Furthermore, significantly increased ANP, H‑FABP and CK‑MB expression levels were detected in the left ventricles of the mice injected with B19V‑VP1u, B19V‑VP1u‑A and B19V‑VP1u‑B, along with enhanced infiltration of lymphocytes. Significantly higher serum IL‑1β, IL‑6, TNF‑α and IFN‑γ levels were also detected in the mice injected with B19V‑VP1u, B19V‑VP1u‑A and B19V‑VP1u‑B. To the best of our knowledge, the findings of the present study were the first to demonstrate that the N‑terminal region (residues 1‑129) of B19V‑VP1u induces an increase in the levels of cardiac injury markers, thus providing evidence for understanding the possible functional regions within B19V‑VP1u.

View Figures

View References

1	Kelly HA, Siebert D, Hammond R, Leydon J, Kiely P and Maskill W: The age-specific prevalence of human parvovirus immunity in Victoria, Australia compared with other parts of the world. Epidemiol Infect. 124:449–457. 2000. View Article : Google Scholar : PubMed/NCBI
2	Cotmore SF, McKie VC, Anderson LJ, Astell CR and Tattersall P: Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol. 60:548–557. 1986. View Article : Google Scholar : PubMed/NCBI
3	Nüesch JPF, Corbau R, Tattersall P and Rommelaere J: Biochemical activities of minute virus of mice nonstructural protein NS1 Are modulated in vitro by the phosphorylation state of the polypeptide. J Virol. 72:8002–8012. 1998. View Article : Google Scholar : PubMed/NCBI
4	Tewary SK, Zhao H, Deng X, Qiu J and Tang L: The human parvovirus B19 non-structural protein 1 N-terminal domain specifically binds to the origin of replication in the viral DNA. Virology. 449:297–303. 2014. View Article : Google Scholar : PubMed/NCBI
5	Moffatt S, Yaegashi N, Tada K, Tanaka N and Sugamura K: Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol. 72:3018–3028. 1998. View Article : Google Scholar : PubMed/NCBI
6	Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M and Sasaki T: Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol. 76:5395–5403. 2002. View Article : Google Scholar : PubMed/NCBI
7	Weigel-Kelley KA, Yoder MC and Srivastava A: Recombinant human parvovirus B19 vectors: Erythrocyte P antigen is necessary but not sufficient for successful transduction of human hematopoietic cells. J Virol. 75:4110–4116. 2001. View Article : Google Scholar : PubMed/NCBI
8	Kurtzman GJ, Cohen BJ, Field AM, Oseas R, Blaese RM and Young NS: Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest. 84:1114–1123. 1989. View Article : Google Scholar : PubMed/NCBI
9	Anderson S, Momoeda M, Kawase M, Kajigaya S and Young NS: Peptides derived from the unique region of B19 parvovirus minor capsid protein elicit neutralizing antibodies in rabbits. Virology. 206:626–632. 1995. View Article : Google Scholar : PubMed/NCBI
10	Mahrholdt H, Wagner A, Deluigi CC, Kispert E, Hager S, Meinhardt G, Vogelsberg H, Fritz P, Dippon J, Bock CT, et al: Presentation, patterns of myocardial damage, and clinical course of viral myocarditis. Circulation. 114:1581–1590. 2006. View Article : Google Scholar : PubMed/NCBI
11	Bogomolovas J, Šimoliūnas E, Rinkūnaitė I, Smalinskaitė L, Podkopajev A, Bironaitė D, Weis CA, Marx A, Bukelskienė V, Gretz N, et al: A novel murine model of parvovirus associated dilated cardiomyopathy induced by immunization with VP1-unique region of parvovirus B19. Biomed Res Int. 2016:16271842016. View Article : Google Scholar : PubMed/NCBI
12	Hatakka A, Klein J, He R, Piper J, Tam E and Walkty A: Acute hepatitis as a manifestation of parvovirus B19 infection. J Clin Microbiol. 49:3422–3424. 2011. View Article : Google Scholar : PubMed/NCBI
13	Komatsuda A, Ohtani H, Nimura T, Yamaguchi A, Wakui H, Imai H and Miura AB: Endocapillary proliferative glomerulonephritis in a patient with parvovirus B19 infection. Am J Kidney Dis. 36:851–854. 2000. View Article : Google Scholar : PubMed/NCBI
14	Ferrari SM, Fallahi P, Antonelli A and Benvenga S: Environmental issues in thyroid diseases. Front Endocrinol (Lausanne). 8:502017. View Article : Google Scholar : PubMed/NCBI
15	Bozzola E, Krzysztofiak A and Cortis E: Neurological impairment and arthritis in an immunocompetent child with human parvovirus B19 chronic infection. Infez Med. 18:187–190. 2010.PubMed/NCBI
16	Hobbs JA and Adamson-Small LA: Parvovirus and thyroid cancer. Semin Oncol. 42:304–308. 2015. View Article : Google Scholar : PubMed/NCBI
17	Page C, François C, Goëb V and Duverlie G: Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses. J Clin Virol. 72:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
18	Pankuweit S, Moll R, Baandrup U, Portig I, Hufnagel G and Maisch B: Prevalence of the parvovirus B19 genome in endomyocardial biopsy specimens. Hum Pathol. 34:497–503. 2003. View Article : Google Scholar : PubMed/NCBI
19	Pankuweit S, Lamparter S, Schoppet M and Maisch B: Parvovirus B19 genome in endomyocardial biopsy specimen. Circulation. 109:e1792004. View Article : Google Scholar : PubMed/NCBI
20	Tschöpe C, Bock CT, Kasner M, Noutsias M, Westermann D, Schwimmbeck PL, Pauschinger M, Poller WC, Kühl U, Kandolf R and Schultheiss HP: High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation. 111:8792005. View Article : Google Scholar : PubMed/NCBI
21	Kühl U, Lassner D, Pauschinger M, Gross UM, Seeberg B, Noutsias M, Poller W and Schultheiss HP: Prevalence of erythrovirus genotypes in the myocardium of patients with dilated cardiomyopathy. J Med Virol. 80:1243–1251. 2008. View Article : Google Scholar : PubMed/NCBI
22	Bültmann BD, Klingel K, Sotlar K, Bock CT, Baba HA, Sauter M and Kandolf R: Fatal parvovirus B19-associated myocarditis clinically mimicking ischemic heart disease: An endothelial cell-mediated disease. Hum Pathol. 34:92–95. 2003. View Article : Google Scholar : PubMed/NCBI
23	Duechting A, Tschöpe C, Kaiser H, Lamkemeyer T, Tanaka N, Aberle S, Lang F, Torresi J, Kandolf R and Bock CT: Human parvovirus B19 NS1 protein modulates inflammatory signaling by activation of STAT3/PIAS3 in human endothelial cells. J Virol. 82:7942–7952. 2008. View Article : Google Scholar : PubMed/NCBI
24	Hii HP, Chiu CC, Lin DW, Shi YF, Hsu TC and Tzang BS: Selective activation of inflammation factors by human parvovirus B19 and human bocavirus VP1 unique region on H9c2 cardiomyocyte. Mol Med Rep. 18:4072–4078. 2018.PubMed/NCBI
25	Nie X, Zhang G, Xu D, Sun X, Li Z, Li X, Zhang X, He F and Li Y: The VP1-unique region of parvovirus B19 induces myocardial injury in mice. Scand J Infect Dis. 42:121–128. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tzang BS, Lin TM, Tsai CC, Hsu JD, Yang LC and Hsu TC: Increased cardiac injury in NZB/W F1 mice received antibody against human parvovirus B19 VP1 unique region protein. Mol Immunol. 48:1518–1524. 2011. View Article : Google Scholar : PubMed/NCBI
27	Chen DY, Chen YM, Tzang BS, Lan JL and Hsu TC: Th17-related cytokines in systemic lupus erythematosus patients with dilated cardiomyopathies: A possible linkage to parvovirus B19 infection. PLoS One. 9:e1138892014. View Article : Google Scholar : PubMed/NCBI
28	Tsai CC, Chiu CC, Hsu JD, Hsu HS, Tzang BS and Hsu TC: Human parvovirus B19 NS1 protein aggravates liver injury in NZB/W F1 mice. PLoS One. 8:e597242013. View Article : Google Scholar : PubMed/NCBI
29	Lin CY, Chiu CC, Cheng J, Lin CY, Shi YF, Tsai CC, Tzang BS and Hsu TC: Antigenicity analysis of human parvovirus B19-VP1u protein in the induction of anti-phospholipid syndrome. Virulence. 9:208–216. 2018. View Article : Google Scholar : PubMed/NCBI
30	Nakashima I, Ota F, Kobayashi T, Kato O and Kato N: The effect of antigen doses and time intervals between antigen injections on secondary, tertiary and quaternary antibody responses. Establishment of hyperimmunization with bovine serum albumin in mice treated with capsular polysaccharide of Klebsiella pneumoniae. Immunology. 26:443–454. 1974.PubMed/NCBI
31	Castiglione F, Mantile F, De Berardinis P and Prisco A: How the interval between prime and boost injection affects the immune response in a computational model of the immune system. Comput Math Methods Med. 2012:8423292012. View Article : Google Scholar : PubMed/NCBI
32	Hsu TC, Chiu CC, Chang SC, Chan HC, Shi YF, Chen TY and Tzang BS: Human parvovirus B19 VP1u Protein as inflammatory mediators induces liver injury in naïve mice. Virulence. 7:110–118. 2016. View Article : Google Scholar : PubMed/NCBI
33	Liu P, Sun M and Sader S: Matrix metalloproteinases in cardiovascular disease. Can J Cardiol. 22 (Suppl B):25B–30B. 2006. View Article : Google Scholar : PubMed/NCBI
34	Liu J and Khalil RA: Matrix metalloproteinase inhibitors as investigational and therapeutic tools in unrestrained tissue remodeling and pathological disorders. Prog Mol Biol Transl Sci. 148:355–420. 2017. View Article : Google Scholar : PubMed/NCBI
35	Kampoli AM, Tousoulis D, Papageorgiou N, Antoniades C, Androulakis E, Tsiamis E, Latsios G and Stefanadis C: Matrix metalloproteinases in acute coronary syndromes: Current perspectives. Curr Top Med Chem. 12:1192–1205. 2012. View Article : Google Scholar : PubMed/NCBI
36	Fares RC, Gomes Jde A, Garzoni LR, Waghabi MC, Saraiva RM, Medeiros NI, Oliveira-Prado R, Sangenis LH, Chambela Mda C, de Araújo FF, et al: Matrix metalloproteinases 2 and 9 are differentially expressed in patients with indeterminate and cardiac clinical forms of Chagas disease. Infect Immun. 81:3600–3608. 2013. View Article : Google Scholar : PubMed/NCBI
37	Edwards BS, Zimmerman RS and Burnett JC Jr: Atrial natriuretic factor: Physiologic actions and implications in congestive heart failure. Cardiovasc Drugs Ther. 1:89–100. 1987. View Article : Google Scholar : PubMed/NCBI
38	Michel JB, Arnal JF and Corvol P: Atrial natriuretic factor as a marker in congestive heart failure. Horm Res. 34:166–168. 1990. View Article : Google Scholar : PubMed/NCBI
39	Rohini A, Agrawal N, Koyani CN and Singh R: Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res. 61:269–280. 2010. View Article : Google Scholar : PubMed/NCBI
40	Vork MM, Glatz JF and van Der Vusse GJ: On the mechanism of long chain fatty acid transport in cardiomyocytes as facilitated by cytoplasmic fatty acid-binding protein. J Theor Biol. 160:207–222. 1993. View Article : Google Scholar : PubMed/NCBI
41	Crisman TS, Claffey KP, Saouaf R, Hanspal J and Brecher P: Measurement of rat heart fatty acid binding protein by ELISA. Tissue distribution, developmental changes and subcellular distribution. J Mol Cell Cardiol. 19:423–431. 1987. View Article : Google Scholar : PubMed/NCBI
42	Sato Y, Kita T, Takatsu Y and Kimura T: Biochemical markers of myocyte injury in heart failure. Heart. 90:1110–1113. 2004. View Article : Google Scholar : PubMed/NCBI
43	Mair J: Progress in myocardial damage detection: New biochemical markers for clinicians. Crit Rev Clin Lab Sci. 34:1–66. 1997. View Article : Google Scholar : PubMed/NCBI
44	Aydin S, Ugur K, Aydin S, Sahin İ and Yardim M: Biomarkers in acute myocardial infarction: Current perspectives. Vasc Health Risk Manag. 15:1–10. 2019. View Article : Google Scholar : PubMed/NCBI
45	Levine B, Kalman J, Mayer L, Fillit HM and Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 323:236–241. 1990. View Article : Google Scholar : PubMed/NCBI
46	Matsumori A: Molecular and immune mechanisms in the pathogenesis of cardiomyopathy-role of viruses, cytokines, and nitric oxide. Jpn Circ J. 61:275–291. 1997. View Article : Google Scholar : PubMed/NCBI
47	Miyao Y, Yasue H, Ogawa H, Misumi I, Masuda T, Sakamoto T and Morita E: Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am Heart J. 126:1299–1304. 1993. View Article : Google Scholar : PubMed/NCBI
48	Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M and Schömig A: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 92:748–755. 1995. View Article : Google Scholar : PubMed/NCBI
49	Dinarello CA: The biological properties of interleukin-1. Eur Cytokine Netw. 5:517–531. 1994.PubMed/NCBI
50	Blum A and Miller H: Role of cytokines in heart failure. Am Heart J. 35:181–186. 1998. View Article : Google Scholar : PubMed/NCBI
51	Carter AB, Monick MM and Hunninghake GW: Both Erk and p38 kinases are necessary for cytokine gene transcription. Am J Respir Cell Mol Biol. 20:751–758. 1999. View Article : Google Scholar : PubMed/NCBI
52	Saikawa T, Anderson S, Momoeda M, Kajigaya S and Young NS: Neutralizing linear epitopes of B19 parvovirus cluster in the VP1 unique and VP1-VP2 junction regions. J Virol. 67:3004–3009. 1993. View Article : Google Scholar : PubMed/NCBI
53	Zuffi E, Manaresi E, Gallinella G, Gentilomi GA, Venturoli S, Zerbini M and Musiani M: Identification of an immunodominant peptide in the parvovirus B19 VP1 unique region able to elicit a long-lasting immune response in humans. Viral Immunol. 14:151–158. 2001. View Article : Google Scholar : PubMed/NCBI
54	Leisi R, Di Tommaso C, Kempf C and Ros C: The receptor-binding domain in the VP1u region of parvovirus B19. Viruses. 8:612016. View Article : Google Scholar : PubMed/NCBI
55	Qiu J, Söderlund-Venermo M and Young NS: Human parvoviruses. Clin Microbiol Rev. 30:43–113. 2017. View Article : Google Scholar : PubMed/NCBI